BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 16900573)

  • 1. A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials.
    Schwartz TA; Denne JS
    Stat Med; 2006 Oct; 25(19):3396-406. PubMed ID: 16900573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
    Lai TL; Shih MC; Zhu G
    Stat Med; 2006 Apr; 25(7):1149-67. PubMed ID: 16189814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some fundamental issues with non-inferiority testing in active controlled trials.
    James Hung HM; Wang SJ; Tsong Y; Lawrence J; O'Neil RT
    Stat Med; 2003 Jan; 22(2):213-25. PubMed ID: 12520558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.
    Pigeot I; Schäfer J; Röhmel J; Hauschke D
    Stat Med; 2003 Mar; 22(6):883-99. PubMed ID: 12627407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints.
    Mielke M; Munk A; Schacht A
    Stat Med; 2008 Nov; 27(25):5093-110. PubMed ID: 18570271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A note on the conservativeness of the confidence interval approach for the selection of non-inferiority margin in the two-arm active-control trial.
    Sankoh AJ
    Stat Med; 2008 Aug; 27(19):3732-42. PubMed ID: 18407575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TACT method for non-inferiority testing in active controlled trials.
    Wang SJ; Hung HM
    Stat Med; 2003 Jan; 22(2):227-38. PubMed ID: 12520559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials.
    Wang SJ; Hung HM; Tsong Y; Cui L
    Stat Med; 2001 Jul; 20(13):1903-12. PubMed ID: 11427948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.
    D'Agostino RB; Massaro JM; Sullivan LM
    Stat Med; 2003 Jan; 22(2):169-86. PubMed ID: 12520555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new test of non-inferiority for anti-infective trials.
    Phillips KF
    Stat Med; 2003 Jan; 22(2):201-12. PubMed ID: 12520557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing non-inferiority: a combination approach.
    Gao P; Ware JH
    Stat Med; 2008 Feb; 27(3):392-406. PubMed ID: 17575568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the three-arm non-inferiority trial including a placebo with a prespecified margin.
    Hida E; Tango T
    Stat Med; 2011 Feb; 30(3):224-31. PubMed ID: 21213340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A framework for two-stage adaptive procedures to simultaneously test non-inferiority and superiority.
    Koyama T; Sampson AR; Gleser LJ
    Stat Med; 2005 Aug; 24(16):2439-56. PubMed ID: 15977285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials.
    Dann RS; Koch GG
    Pharm Stat; 2008; 7(2):130-41. PubMed ID: 17526060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and regulatory experiences with non-inferiority trial design without placebo arm.
    Hung HM; Wang SJ; O'Neill R
    Biom J; 2009 Apr; 51(2):324-34. PubMed ID: 19358213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple-arm superiority and non-inferiority designs with various endpoints.
    Chang M
    Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On non-inferiority margin and statistical tests in active control trials.
    Chow SC; Shao J
    Stat Med; 2006 Apr; 25(7):1101-13. PubMed ID: 16345042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-inferiority trials: the 'at least as good as' criterion with dichotomous data.
    Laster LL; Johnson MF; Kotler ML
    Stat Med; 2006 Apr; 25(7):1115-30. PubMed ID: 16381070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat.
    Matilde Sanchez M; Chen X
    Stat Med; 2006 Apr; 25(7):1169-81. PubMed ID: 16397861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.